FIGO stage IB clear cell carcinoma and adenocarcinoma of uterine cervix.
- Author:
Jin Hee KIM
1
;
Eun Sun CHOI
;
Dae Yeon KIM
;
Dae Sik SUH
;
Jong Hyeok KIM
;
Yong Man KIM
;
Young Tak KIM
;
Joo Hyun NAM
;
Jung Eun MOK
Author Information
1. Department of Obstetric and Gynecology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea. kdyog@amc.seoul.kr
- Publication Type:Original Article ; Multicenter Study
- Keywords:
Clear cell carcinoma;
Adenocarcinoma;
Uterine cervix
- MeSH:
Adenocarcinoma*;
Cervix Uteri*;
Disease-Free Survival;
Female;
Humans;
Hysterectomy;
Lymph Node Excision;
Lymph Nodes;
Neoplasm Metastasis;
Prognosis;
Radiotherapy;
Retrospective Studies;
Survival Rate
- From:Korean Journal of Gynecologic Oncology
2005;16(4):307-315
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To compare the clinical features and prognosis of patients with clear cell carcinoma (CCA) and adenocarcinoma (ACA)of the uterine cervix. METHODS: We have performed retrospective clinical study on 5 patients diagnosed as CCA and 55 patients diagnosed as ACA from November 2000 to December 2004. Demographic data, pathologic findings, treatments and survival time were reviewed. RESULTS: The mean age of patients with CCA and ACA was 31.5 or 30.4 years respectively and all patients were FIGO stage IB. Among the 5 patients of CCA, 4 patients have underwent radical hysterectomy (RH) and one patient have treated with radiotherapy only. Among the 55 patients of ACA, 50 patients have underwent RH and pelvic lymph node dissection (PLND), paraaortic lymph node sampling (PALNS) and the other have underwent only bilateral salphingoophorectomy (BSO) and PLND. There are no significant difference on age, tumor size, depth of invasion, parametrial involvement, vaginal involvement and pelvic lymph node metastasis (p>0.05). The mean survival time of CCA and ACA was 42.5 and 43.2 months respectively (p=0.32). The recurrent rate of CCA and ACA are 25% and 5.45% (p=0.30) and the disease free survival of CCA and ACA are 18.7 months and 43.6 months respectively (p=0.054). CONCLUSION: There were no significant difference on clinical features and prognosis of FIGO stage Ib CCA and ACA. Large scaled prospective multicenter trials will be able to provide a decision for prognosis and proper therapy.
